{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T15:10:56Z","timestamp":1791040256177,"version":"4.1.0"},"reference-count":24,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2008,2,26]],"date-time":"2008-02-26T00:00:00Z","timestamp":1203984000000},"content-version":"vor","delay-in-days":25,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Tropical Med Int Health"],"published-print":{"date-parts":[[2008,2]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p><jats:bold>Objective\u2002<\/jats:bold> To compare the cost\u2010effectiveness of eflornithine and melarsoprol in the treatment of human African trypanosomiasis.<\/jats:p><jats:p><jats:bold>Method\u2002<\/jats:bold> We used data from a M\u00e9decins Sans Fronti\u00e8res treatment project in Caxito, Angola to do a formal cost\u2010effectiveness analysis, comparing the efficiency of an eflornithine\u2010based approach with melarsoprol. Endpoints calculated were: cost per death avoided; incremental cost per additional life saved; cost per years of life lost (YLL) averted; incremental cost per YLL averted. Sensitivity analysis was done for all parameters for which uncertainty existed over the plausible range. We did an analysis with and without cost of trypanocidal drugs included.<\/jats:p><jats:p><jats:bold>Results\u2002<\/jats:bold> Effectiveness was 95.6% for melarsoprol and 98.7% for eflornithine. Cost\/patient was 504.6 for melarsoprol and 552.3 for eflornithine, cost per life saved was 527.5\u2003USD for melarsoprol and 559.8\u2003USD for eflornithine without cost of trypanocidal drugs but it increases to 600.4\u2003USD and 844.6\u2003USD per patient saved and 627.6\u2003USD and 856.1\u2003USD per life saved when cost of trypanocidal drugs are included. Incremental cost\u2010effectiveness ratio is 1596\u2003USD per additional life saved and 58\u2003USD per additional life year saved in the baseline scenario without cost of trypanocidal drugs but it increases to 8169\u2003USD per additional life saved and 299\u2003USD per additional life year saved if costs of trypanocidal drugs are included.<\/jats:p><jats:p><jats:bold>Conclusion\u2002<\/jats:bold> Eflornithine saves more lives than melarsoprol, but melarsoprol is slightly more cost\u2010effective. Switching from melarsoprol to eflornithine can be considered as a cost\u2010effective option according to the WHO choice criteria.<\/jats:p>","DOI":"10.1111\/j.1365-3156.2007.01999.x","type":"journal-article","created":{"date-parts":[[2010,8,11]],"date-time":"2010-08-11T22:05:45Z","timestamp":1281564345000},"page":"265-271","source":"Crossref","is-referenced-by-count":17,"title":["Eflornithine is a cost\u2010effective alternative to melarsoprol for the treatment of second\u2010stage human West African trypanosomiasis in Caxito, Angola"],"prefix":"10.1111","volume":"13","author":[{"given":"J.","family":"Robays","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. E.","family":"Raguenaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Josenando","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Boelaert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2008,2,26]]},"reference":[{"key":"e_1_2_5_2_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.331.7525.1107"},{"key":"e_1_2_5_3_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-3156.2001.00710.x"},{"issue":"1","key":"e_1_2_5_4_1","doi-asserted-by":"crossref","first-page":"S49","DOI":"10.1007\/s00436-002-0766-5","article-title":"Eflornithine for the treatment of human African trypanosomiasis","volume":"90","author":"Burri C","year":"2003","journal-title":"Parasitology Research"},{"key":"e_1_2_5_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)02141-3"},{"key":"e_1_2_5_6_1","doi-asserted-by":"publisher","DOI":"10.1086\/432576"},{"key":"e_1_2_5_7_1","volume-title":"Macroeconomics and Health, Investing in Health for Economic Development","author":"Commission for Macroeconomics and Health","year":"2001"},{"key":"e_1_2_5_8_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.38652.550278.7C"},{"key":"e_1_2_5_9_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.38658.675243.94"},{"key":"e_1_2_5_10_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMsa060247"},{"key":"e_1_2_5_11_1","first-page":"171","article-title":"Therapeutic failure of melarsoprol among patients treated for late stage T. b. gambiense human African trypanosomiasis in Uganda","volume":"92","author":"Legros D","year":"1999","journal-title":"Bulletin de la Soci\u00e9t\u00e9 de Pathologie Exotique"},{"key":"e_1_2_5_12_1","first-page":"559","article-title":"L\u2019Eflornithine dans le traitement de la maladie du sommeil","volume":"63","author":"Louis FJ","year":"2003","journal-title":"M\u00e9decine Tropicale"},{"key":"e_1_2_5_13_1","doi-asserted-by":"publisher","DOI":"10.3201\/eid1109.041020"},{"key":"e_1_2_5_14_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-3156.2001.00712.x"},{"key":"e_1_2_5_15_1","volume-title":"The Global Burden of Disease: A Comprehensive Assessment of Mortality and Disability From Diseases, Injuries and Risk Factors in 1990 and Projected to 2020. Global Burden of Disease and Injury Series","author":"Murray CJL","year":"1996"},{"key":"e_1_2_5_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(03)12655-4"},{"key":"e_1_2_5_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(89)92340-4"},{"key":"e_1_2_5_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/0035-9203(94)90430-8"},{"key":"e_1_2_5_19_1","first-page":"1284","article-title":"Short\u2010course eflornithine in Gambian trypanosomiasis: a multicentre randomized controlled trial","volume":"78","author":"Pepin J","year":"2000","journal-title":"Bulletin of the World Health Organization"},{"key":"e_1_2_5_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/hec.4730040404"},{"key":"e_1_2_5_21_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pctr.0010039"},{"key":"e_1_2_5_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-3156.2006.01768.x"},{"key":"e_1_2_5_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(04)16940-7"},{"key":"e_1_2_5_24_1","doi-asserted-by":"publisher","DOI":"10.1086\/429929"},{"key":"e_1_2_5_25_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-3156.2001.00724.x"}],"container-title":["Tropical Medicine &amp; International Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-3156.2007.01999.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-3156.2007.01999.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,14]],"date-time":"2023-10-14T19:14:51Z","timestamp":1697310891000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-3156.2007.01999.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,2]]},"references-count":24,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2008,2]]}},"alternative-id":["10.1111\/j.1365-3156.2007.01999.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-3156.2007.01999.x","archive":["Portico"],"relation":{},"ISSN":["1360-2276","1365-3156"],"issn-type":[{"value":"1360-2276","type":"print"},{"value":"1365-3156","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,2]]}}}